PE20151144A1 - Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias - Google Patents

Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias

Info

Publication number
PE20151144A1
PE20151144A1 PE2015000712A PE2015000712A PE20151144A1 PE 20151144 A1 PE20151144 A1 PE 20151144A1 PE 2015000712 A PE2015000712 A PE 2015000712A PE 2015000712 A PE2015000712 A PE 2015000712A PE 20151144 A1 PE20151144 A1 PE 20151144A1
Authority
PE
Peru
Prior art keywords
gamma
modulators
treatment
alkyl
ror
Prior art date
Application number
PE2015000712A
Other languages
English (en)
Inventor
Fangbin Han
Hui Lei
Xichen Lin
Qinqhua Meng
Yonghui Wang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49709687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20151144A1 publication Critical patent/PE20151144A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La invencion se refiere a compuestos de formula I como moduladores del receptor huerfano gamma relacionado con retinoides (RORgamma) y su uso en el tratamiento de enfermedades mediadas por RORgamma, como esclerosis multiple, artritis reumatoide, psoriasis, etc. Donde R1 es alquilo C1-C6, cicloalquilo C3-C7, etc; R2 es halo o alquilo C1-C3; R3 es halo o metilo; R4 es H o metilo; R5 es alquilo C1-C3; R6 es alquilo C1-C3; R7 es alquilo C1-C7, etc; cada K es 0 o 1 y cada p es 0 o 1. Los compuestos preferidos son: (S)-N-(3-((4-(ciclopentancarbonil)-3-metilpiperazin-1-il)metil)-5-fluoro-2-metilfenil)-2-metilpirimidin-5-carboxamida(E20); y (S)-N-(5-cloro-3-((4-(ciclopentancarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6- metilnicotinamida (E62); entre otros
PE2015000712A 2012-12-06 2013-12-05 Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias PE20151144A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2012001636 2012-12-06
CN2013000182 2013-02-25
CN2013000803 2013-07-01

Publications (1)

Publication Number Publication Date
PE20151144A1 true PE20151144A1 (es) 2015-08-02

Family

ID=49709687

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000712A PE20151144A1 (es) 2012-12-06 2013-12-05 Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias

Country Status (33)

Country Link
US (1) US10005731B2 (es)
EP (2) EP3219711A1 (es)
JP (1) JP6279605B2 (es)
KR (1) KR20150092244A (es)
CN (1) CN105121430B (es)
AR (1) AR093818A1 (es)
AU (1) AU2013354109B2 (es)
BR (1) BR112015013137B1 (es)
CA (1) CA2894016C (es)
CL (1) CL2015001557A1 (es)
CR (1) CR20150302A (es)
CY (1) CY1118932T1 (es)
DK (1) DK2928885T3 (es)
EA (1) EA026437B1 (es)
ES (1) ES2626390T3 (es)
HK (1) HK1214814A1 (es)
HR (1) HRP20170638T1 (es)
HU (1) HUE033212T2 (es)
IL (1) IL239082A0 (es)
LT (1) LT2928885T (es)
ME (1) ME02696B (es)
MX (1) MX2015007180A (es)
PE (1) PE20151144A1 (es)
PH (1) PH12015501244A1 (es)
PL (1) PL2928885T3 (es)
PT (1) PT2928885T (es)
RS (1) RS55875B1 (es)
SG (1) SG11201504200TA (es)
SI (1) SI2928885T1 (es)
TW (1) TW201427959A (es)
UY (1) UY35174A (es)
WO (1) WO2014086894A1 (es)
ZA (1) ZA201503666B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017335A1 (en) * 2013-07-30 2015-02-05 Boehringer Ingelheim International Gmbh Azaindole compounds as modulators of rorc
EP3527569B1 (en) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye
JP2017516800A (ja) 2014-05-28 2017-06-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
JP6759110B2 (ja) * 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
CN107001342B (zh) * 2014-05-28 2020-02-07 葛兰素史密斯克莱知识产权发展有限公司 新化合物
CN104292208A (zh) * 2014-09-09 2015-01-21 上海师范大学 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TW201625588A (zh) * 2014-11-05 2016-07-16 第一三共股份有限公司 環狀胺衍生物
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CA2975060C (en) * 2015-01-30 2019-09-03 Pfizer Inc. Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
CN108463458B (zh) * 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
KR102490140B1 (ko) * 2016-07-13 2023-01-19 레오 파마 에이/에스 레티노이드-관련 희귀 수용체 감마의 신규한 헤테로방향족 조절제
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途
US11001552B2 (en) 2017-07-18 2021-05-11 Lonza Ltd Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
UA126583C2 (uk) 2017-07-24 2022-11-02 Вітае Фармасьютікалс, Ллс ІНГІБІТОРИ ROR<font face="Symbol">g</font>
CN108752185A (zh) * 2018-07-17 2018-11-06 成都道合尔医药技术有限公司 一种1-氟-环戊甲酸的合成方法
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
CN110862319A (zh) * 2019-12-04 2020-03-06 深圳振强生物技术有限公司 奥扎格雷杂质的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
JP5178526B2 (ja) * 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
JP5902029B2 (ja) 2011-04-28 2016-04-13 日本たばこ産業株式会社 アミド化合物およびその医薬用途
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
WO2013160418A1 (en) 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
AU2014340107B2 (en) 2013-10-25 2017-08-31 Glaxosmithkline Llc Novel compounds
US10286000B2 (en) 2013-10-25 2019-05-14 St. Jude Children's Research Hospital, Inc. Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
CN107001342B (zh) 2014-05-28 2020-02-07 葛兰素史密斯克莱知识产权发展有限公司 新化合物
JP2017516800A (ja) 2014-05-28 2017-06-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
JP6759110B2 (ja) 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物

Also Published As

Publication number Publication date
CN105121430B (zh) 2017-06-16
PH12015501244A1 (en) 2015-08-10
KR20150092244A (ko) 2015-08-12
US10005731B2 (en) 2018-06-26
CA2894016A1 (en) 2014-06-12
CY1118932T1 (el) 2018-01-10
CL2015001557A1 (es) 2015-10-02
CR20150302A (es) 2015-08-10
WO2014086894A1 (en) 2014-06-12
PT2928885T (pt) 2017-06-30
JP6279605B2 (ja) 2018-02-14
AR093818A1 (es) 2015-06-24
EP3219711A1 (en) 2017-09-20
CN105121430A (zh) 2015-12-02
US20150299121A1 (en) 2015-10-22
LT2928885T (lt) 2017-05-25
HK1214814A1 (zh) 2016-08-05
CA2894016C (en) 2020-12-22
SG11201504200TA (en) 2015-06-29
MX2015007180A (es) 2015-10-14
BR112015013137A2 (pt) 2017-07-11
AU2013354109B2 (en) 2016-06-16
AU2013354109A1 (en) 2015-06-11
HUE033212T2 (hu) 2017-11-28
EP2928885A1 (en) 2015-10-14
DK2928885T3 (en) 2017-05-15
IL239082A0 (en) 2015-07-30
RS55875B1 (sr) 2017-08-31
PL2928885T3 (pl) 2017-09-29
SI2928885T1 (sl) 2017-06-30
ME02696B (me) 2017-10-20
UY35174A (es) 2014-06-30
ZA201503666B (en) 2016-02-24
JP2016501250A (ja) 2016-01-18
ES2626390T3 (es) 2017-07-24
TW201427959A (zh) 2014-07-16
EA201591059A1 (ru) 2015-09-30
BR112015013137B1 (pt) 2022-05-10
EA026437B1 (ru) 2017-04-28
HRP20170638T1 (hr) 2017-06-30
EP2928885B1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
PE20151144A1 (es) Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
DOP2016000140A (es) Inhibidores de syk
CL2016002348A1 (es) Agonistas del receptor muscarínico
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
SV2016005192A (es) Composiciones y métodos para modular los receptores x farnesoides
PE20180037A1 (es) Nuevos derivados de piridina
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
CR20140305A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios
NI201300068A (es) Moduladores del receptor de glucagón
UY35700A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
ECSP11010932A (es) Compuestos de azaindazol como antagonistas del receptor de ccr1
UY35288A (es) Piridonamidas como moduladores de canales de sodio
EA201791271A1 (ru) ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
ECSP12011983A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
PE20150224A1 (es) Inhibidores del nampt
UY36709A (es) Moduladores de ror gamma (ror¿)
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
PE20151536A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
NI201500050A (es) Benzamidas
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2

Legal Events

Date Code Title Description
FD Application declared void or lapsed